By analyzing 142 cases of adenocarcinoma with known EGFR mutation status, we found no significant correlation for DR4 expression between EGFR WT and mutant tumors (Table S3), indicating that EGFR mutation does not impact DR4 expression in NSCLCs. Here, EGFR is linked to adenocarcinoma.